Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1960 3
1962 2
1965 1
1966 2
1967 1
1968 2
1969 1
1970 3
1971 1
1972 2
1974 2
1975 2
1977 2
1978 1
1979 1
1980 3
1981 2
1983 1
1984 2
1985 1
1986 2
1990 2
1991 1
1992 2
1993 1
1994 2
1995 2
1996 4
1997 7
1998 8
1999 10
2000 6
2001 13
2002 9
2003 5
2004 3
2005 4
2006 4
2007 4
2008 7
2009 3
2010 9
2011 6
2012 5
2013 9
2014 15
2015 12
2016 20
2017 13
2018 17
2019 16
2020 18
2021 21
2022 10
2023 13
2024 25
2025 22
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

329 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hamamoto w[au] (20 results)?
CD83 as a novel prognostic biomarker for diffuse large B-cell lymphoma arising in immune deficiency/dysregulation among rheumatoid arthritis patients treated with methotrexate.
Sawada K, Takahashi T, Fukumura Y, Onagi H, Ashizawa K, Yamashita T, Yamamoto W, Takayanagi N, Adachi A, Kashimura M, Tabayashi T, Tamaru JI, Higashi M, Momose S. Sawada K, et al. Among authors: yamamoto w. J Clin Exp Hematop. 2026;66(1):27-36. doi: 10.3960/jslrt.25087. J Clin Exp Hematop. 2026. PMID: 41922226 Free article.
Clinical outcomes of molecular-targeted therapies for rheumatoid arthritis: comparison between orthopaedic surgeons and rheumatologists in the multicenter retrospective ANSWER cohort.
Etani Y, Okita Y, Tsujimoto K, Noguchi T, Murata K, Fujii T, Shirasugi I, Yamashita M, Nagai K, Yoshikawa A, Hashimoto M, Okano T, Nozaki Y, Itami T, Son Y, Makino H, Yamamoto W, Kumanogoh A, Okada S, Nakata K, Ebina K. Etani Y, et al. Among authors: yamamoto w. Clin Rheumatol. 2026 Apr 1. doi: 10.1007/s10067-026-08061-7. Online ahead of print. Clin Rheumatol. 2026. PMID: 41920235
Mode of action-specific and cause-specific retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in anti-SS-A antibody-positive rheumatoid arthritis: The ANSWER cohort study.
Nishisaka K, Okano T, Imai T, Tsubosaka M, Kamenaga T, Nakano N, Hayashi S, Yamamoto W, Onishi A, Murakami K, Tsujimoto K, Katsushima M, Yoshikawa A, Kotani T, Amuro H, Son Y, Itami T, Nozaki Y, Nose Y, Yamashita M, Shirasugi I, Yamada H, Nishimura K, Ueda Y, Sendo S, Hashimoto M, Kuroda R, Saegusa J. Nishisaka K, et al. Among authors: yamamoto w. PLoS One. 2026 Mar 18;21(3):e0344747. doi: 10.1371/journal.pone.0344747. eCollection 2026. PLoS One. 2026. PMID: 41849340 Free PMC article.
Complexity and Challenges of Translating the Dark Zone Signature Into Immunohistochemistry in Diffuse Large B-Cell Lymphoma.
Momose S, Sawada K, Nedeva T, Yamamoto W, Yamashita T, Imada H, Takayanagi N, Naganuma K, Takahashi Y, Tabayashi T, Adachi A, Higashi M, Scott DW, Rosenwald A, Rauert-Wunderlich H. Momose S, et al. Among authors: yamamoto w. Mod Pathol. 2026 Apr;39(4):100979. doi: 10.1016/j.modpat.2026.100979. Epub 2026 Feb 24. Mod Pathol. 2026. PMID: 41747827
Two-Photon-Excited Photoinduced Force Microscopy.
Tamura T, Sagami N, Sasaki T, Yamamoto W, Oketani R, Hiramatsu K. Tamura T, et al. Among authors: yamamoto w. Nano Lett. 2026 Jan 14;26(1):51-57. doi: 10.1021/acs.nanolett.5c04444. Epub 2025 Dec 20. Nano Lett. 2026. PMID: 41420627
Rituximab versus intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: a multicentre REVEAL cohort study.
Miyake H, Okazaki A, Matsuda S, Masuda Y, Kotani T, Hatta M, Shiomi M, Watanabe R, Hashimoto M, Oka H, Sumitomo S, Jo K, Fujiki Y, Yamamoto W, Taniguchi T, Shoji M, Manabe A, Hiwa R. Miyake H, et al. Among authors: yamamoto w. Mod Rheumatol. 2025 Dec 12:roaf124. doi: 10.1093/mr/roaf124. Online ahead of print. Mod Rheumatol. 2025. PMID: 41384758
Baseline neutrophil-to-lymphocyte ratio predicts drug retention of IL-6 inhibitors and JAK inhibitors in RA: the ANSWER cohort study.
Fujisawa Y, Watanabe R, Okano T, Onishi A, Murakami K, Ebina K, Yamada H, Yamashita M, Takeuchi T, Yoshikawa A, Son Y, Makino H, Nozaki Y, Itami T, Yamamoto W, Yano Y, Togashi T, Katsushima M, Fukumoto K, Yamada S, Hashimoto M. Fujisawa Y, et al. Among authors: yamamoto w. Rheumatology (Oxford). 2026 Feb 4;65(2):keaf602. doi: 10.1093/rheumatology/keaf602. Rheumatology (Oxford). 2026. PMID: 41212522
Clinical efficacy of JAK inhibitors for RA patients with poor-prognosis factors: the ANSWER cohort study.
Nozaki Y, Murata K, Onishi A, Tsujimoto K, Yamamoto W, Yamada H, Sendo S, Hashimoto M, Okano T, Shiba H, Hiramatsu Y, Son Y, Yoshida N, Fukuda R, Morimoto Y, Kishimoto K, Itami T, Tomita D, Ashida C, Shiga T, Kinoshita K. Nozaki Y, et al. Among authors: yamamoto w. Rheumatology (Oxford). 2026 Jan 8;65(1):keaf552. doi: 10.1093/rheumatology/keaf552. Rheumatology (Oxford). 2026. PMID: 41159415
329 results